RecruitingPhase 2

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

United States57 participantsStarted 2022-09-12

Plain-language summary

The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.

Who can participate

Age range1 Year – 39 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓--A serum creatinine \< 1.5 Upper Limit normal (ULN) based on age and gender.

What they're measuring

Progression free survival rate (PFS)

Timeframe: Up to 12 months

Changes in scores on the Physical functioning subscale of the Pediatric Quality of Life Inventory (PedsQL) over time

Timeframe: Up to 12 months

Trial details

NCT IDNCT05465174

SponsorSabine Mueller, MD, PhD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-03-01

Contact for this trial

PNOC Operations Office

877-827-3222 PNOC029@ucsf.edu

View on ClinicalTrials.gov More Craniopharyngioma, Child trials